Research progress of optimized mesenchymal stem cells on the treatment of end-stage liver diseases
10.3760/cma.j.cn113884-20220325-00128
- VernacularTitle:优化的间充质干细胞在终末期肝病中的研究进展
- Author:
Xinru ZHANG
1
;
Hongli SONG
Author Information
1. 天津医科大学一中心临床学院，天津 300192
- Keywords:
Mesenchymal stromal cells;
End stage liver disease;
Prognosis
- From:
Chinese Journal of Hepatobiliary Surgery
2022;28(8):624-628
- CountryChina
- Language:Chinese
-
Abstract:
End-stage liver disease refers to the advanced stage of liver disease caused by various acute and chronic liver damage, of which decompensated cirrhosis and liver failure are most common. Currently, liver transplantation is the most effective treatment option for patients with end-stage liver disease, but several limitations regarding transplantation currently restrict its application. Mesenchymal stem cells are the potential treatment option for end-stage liver disease because of the biological properties such as multidirectional differentiation, paracrine and immunomodulatory properties, as well as anti-inflammatory, anti-apoptotic and anti-fibrosis, but the therapeutic effect is affected by low homing rate, poor colonization and low conversion rate. The researchers aimed to improve them through genetic modification, chemical or hypoxic pretreatment, and three dimensional culture. This article reviewed and discussed the pretreatment methods, their application status of treatment for end-stage liver disease and the existing problems.
